{
    "nctId": "NCT05161195",
    "briefTitle": "Roll-over Study to Allow Continued Access to Ribociclib",
    "officialTitle": "A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study",
    "overallStatus": "RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 137,
    "primaryOutcomeMeasure": "Percentage of participants with treatment-emergent adverse events (AES)",
    "eligibilityCriteria": "Key inclusion Criteria:\n\n1. Currently participating in a Novartis sponsored global study (parent study), receiving treatment with ribociclib in combination with other drugs, and the parent study has fulfilled its primary objective(s)\n2. Must have been receiving treatment with ribociclib for at least 6 cycles in the parent study\n3. Currently has evidence of clinical benefit as determined by the Investigator\n\nKey exclusion Criteria:\n\n1. Permanent discontinuation of ribociclib in the parent study\n2. Currently has unresolved toxicities for which ribociclib dosing has been interrupted in the parent study 3. Local access to commercially available ribociclib and reimbursed\n\nOther protocol-defined inclusion/exclusion criteria may apply at the end",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}